Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply.
Adriaan VolkersTessa StraatmijerMarjolijn DuijvesteinMark LöwenbergAndrea van der MeulenGeert D'HaensPublished in: Alimentary pharmacology & therapeutics (2023)